What it's for (Indications)
- The Haemophilus influenzae type b (Hib) vaccine, exemplified by Vaxem Hib, is specifically indicated for active immunization against invasive diseases caused by *Haemophilus influenzae* type b.
- These severe and potentially life-threatening infections primarily affect infants and young children under five years of age, representing a significant cause of pediatric morbidity and mortality worldwide.
- The scope of diseases prevented by the Hib vaccine includes bacterial meningitis, which can lead to severe neurological sequelae or death; epiglottitis, a rapid and severe swelling of the epiglottis that can cause life-threatening airway obstruction; septicaemia (blood poisoning); cellulitis involving the face or head; septic arthritis; and pneumonia.
- The vaccine is a cornerstone of pediatric public health programs, aiming to drastically reduce the incidence of these devastating infections.
- Furthermore, it may be indicated for certain high-risk individuals beyond early childhood, such as those with asplenia (anatomical or functional), sickle cell disease, HIV infection, or undergoing immunosuppressive therapy, who are at increased susceptibility to severe Hib infections.
- This prophylactic measure is designed to induce robust and protective immunity against the capsular polysaccharide of the Hib bacterium, thereby preventing its systemic dissemination and associated pathologies.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The standard dosage for the Haemophilus influenzae type b (Hib) vaccine, such as Vaxem Hib, is a 0.5 mL intramuscular (IM) injection. The typical primary vaccination series for infants generally consists of three doses administered at approximately 2, 4, and 6 months of age, with the first dose commonly given at 2 months. This schedule aligns with many national immunization programs. Following the completion of the primary series, a booster dose is strongly recommended to ensure sustained and robust immunity, typically administered between 12 and 15 months of age. If vaccination is initiated later in infancy, the recommended schedule may vary; for example, infants commencing vaccination at 7-11 months of age may receive two primary doses separated by 1-2 months, followed by a booster dose at 12-15 months of age. For unvaccinated children aged 15 months to 5 years, a single dose is generally sufficient to achieve protection. Specific vaccination schedules can differ based on local or national immunization guidelines and the particular type of Hib conjugate vaccine formulation being used (e.g., some formulations may require fewer primary doses when initiated at older ages). It is imperative that healthcare professionals adhere to the most current official recommendations for administration to ensure optimal vaccine effectiveness and patient protection. |
Safety & Warnings
Common Side Effects
- Potential side effects include local (skin) reactions, fever, malaise (generalized feeling of illness and discomfort), and rarely, neurological disturbances.
Serious Warnings
- Black Box Warning: None
- Caution is advised during pregnancy, as there is a potential for harm to the unborn child.
- Healthcare professionals should be consulted regarding vaccination during pregnancy or lactation.
How it Works (Mechanism of Action)
The Haemophilus influenzae type b (Hib) vaccine operates as a highly effective conjugate vaccine, a sophisticated immunological strategy designed to overcome the inherent poor immunogenicity of the Hib bacterial capsule in infants. The core active component of the vaccine is the purified capsular polysaccharide of *Haemophilus influenzae* type b, specifically Polyribosylribitol Phosphate (PRP). In its native, unconjugated form, PRP acts as a T-cell independent antigen. This means it can directly stimulate B lymphocytes to produce antibodies but typically elicits a weak, transient antibody response and does not induce immunological memory, especially in young infants whose immune systems are immature. To circumvent this limitation and enhance immunogenicity, the PRP polysaccharide is covalently linked, or 'conjugated,' to a carrier protein. Common carrier proteins include tetanus toxoid, diphtheria toxoid, or meningococcal outer membrane protein complex. This conjugation transforms the T-cell independent PRP into a T-cell dependent antigen. Upon administration, antigen-presenting cells process the conjugated antigen and present peptides derived from the carrier protein to T helper cells. These activated T helper cells then provide crucial co-stimulation to B lymphocytes that recognize the PRP component. This synergistic interaction leads to a robust, high-affinity, and long-lasting anti-PRP antibody response, along with the generation of immunological memory. The produced anti-PRP antibodies are critical for opsonization, complement activation, and direct lysis of Hib bacteria, thereby effectively preventing invasive disease by neutralizing the pathogen and facilitating its clearance from the host.